{
  "id": "6020b8811cb411341a000089",
  "type": "list",
  "question": "Which cancers can be treated with Selpercatinib?",
  "ideal_answer": "Selpercatinib was recently approved by the US FDA for the treatment of RET fusion-positive non-small-cell lung cancer, RET fusion-positive thyroid cancer and RET-mutant medullary thyroid cancer.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/33150799",
    "http://www.ncbi.nlm.nih.gov/pubmed/33007380",
    "http://www.ncbi.nlm.nih.gov/pubmed/33272981",
    "http://www.ncbi.nlm.nih.gov/pubmed/33161056",
    "http://www.ncbi.nlm.nih.gov/pubmed/32493697",
    "http://www.ncbi.nlm.nih.gov/pubmed/32557397",
    "http://www.ncbi.nlm.nih.gov/pubmed/33082208",
    "http://www.ncbi.nlm.nih.gov/pubmed/33239432",
    "http://www.ncbi.nlm.nih.gov/pubmed/31988000",
    "http://www.ncbi.nlm.nih.gov/pubmed/32846061",
    "http://www.ncbi.nlm.nih.gov/pubmed/32846060",
    "http://www.ncbi.nlm.nih.gov/pubmed/33169506"
  ],
  "snippets": [
    {
      "text": "BACKGROUND: Selpercatinib (LOXO-292) and pralsetinib (BLU-667) are highly potent RET-selective protein tyrosine kinase inhibitors (TKIs) for treating advanced RET-altered thyroid cancers and non-small cell lung cancer (NSCLC). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33161056",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Based on results from the phase I/II LIBRETTO-001 trial, selpercatinib was recently approved by the US FDA for the treatment of RET fusion-positive non-small-cell lung cancer, RET fusion-positive thyroid cancer and RET-mutant medullary thyroid cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32557397",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The FDA has greenlighted selpercatinib, the first targeted therapy for RET-altered non-small cell lung cancer (NSCLC) and certain types of thyroid cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32493697",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTRODUCTION: Novel rearranged in transfection (RET)-specific tyrosine kinase inhibitors (TKIs) such as selpercatinib (LOXO-292) have shown unprecedented efficacy in tumors positive for RET fusions or mutations, notably RET fusion-positive NSCLC and RET-mutated medullary thyroid cancer (MTC).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31988000",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Neoadjuvant selpercatinib for advanced medullary thyroid cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33169506",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Recently, highly potent next generation selective RET inhibitors have been clinically validated, and selpercatinib was recently Food and Drug Administration (FDA)-approved for advanced MTC. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33169506",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE: Selpercatinib and pralsetinib induce deep and durable responses in advanced RET fusion-positive lung and thyroid cancer patients. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33272981",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "RET-selective inhibitors selpercatinib (LOXO-292) and pralsetinib (BLU-667) recently demonstrated favorable antitumor activity and safety profiles in advanced RET fusion-positive NSCLC, and both have received approval by the US Food and Drug Administration for this indication. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33007380",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: In this phase 1-2 trial, selpercatinib showed durable efficacy with mainly low-grade toxic effects in patients with medullary thyroid cancer with and without previous vandetanib or cabozantinib treatment. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32846061",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33082208",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BACKGROUND: Selpercatinib (LOXO-292) and pralsetinib (BLU-667) are highly potent RET-selective protein tyrosine kinase inhibitors (TKIs) for treating advanced RET-altered thyroid cancers and non-small cell lung cancer (NSCLC).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33161056",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "On May 8, 2020, the Food and Drug Administration granted accelerated approval to selpercatinib for 1) adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC), 2) adult and pediatric patients \u226512 years of age with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy, and 3) adult and pediatric patients \u226512 years of age with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). Approval was granted based on the clinically importa",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33239432",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " on results from the phase I/II LIBRETTO-001 trial, selpercatinib was recently approved by the US FDA for the treatment of RET fusion-positive non-small-cell lung cancer, RET fusion-positive thyroid cancer and RET-mutant medullary thyroid cancer. This art",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32557397",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Selpercatinib, a novel, highly selective and potent, inhibitor of RET, demonstrated clinically meaningful antitumor activity with manageable toxicity in heavily pretreated and treatment-naive RET fusion-positive\u00a0non-small-cell lung cancer patients in a Phase I/II clinical tr",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33150799",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The FDA has greenlighted selpercatinib, the first targeted therapy for RET-altered non-small cell lung cancer (NSCLC) and certain types of thyroid cancer. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32493697",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Selpercatinib (LOXO-292) and pralsetinib (BLU-667) are highly potent RET-selective protein tyrosine kinase inhibitors (TKIs) for treating advanced RET-altered thyroid cancers and non-small cell lung cancer (NSCL",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33161056",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "NSCLC). RET-selective inhibitors selpercatinib (LOXO-292) and pralsetinib (BLU-667) recently demonstrated favorable antitumor activity and safety profiles in advanced RET fusion-positive NSCLC, and both have received approval by the US Food and Drug Administration for this indication",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33007380",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ial. LIBRETTO-431 (NCT04194944) is a randomized, global, multicenter, open-label, Phase III trial, evaluating selpercatinib versus carboplatin or cisplatin and pemetrexed chemotherapy with or without pembrolizumab in treatment-naive patients with locally advanced/metastatic RET fusion-positive nonsquamous non-small-cell lung cancer",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33150799",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Selpercatinib is a highly selective RET kinase inhibitor that has recently been approved by the FDA in lung and thyroid cancers with activating RET gene fusions and mutations.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33082208",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Selpercatinib (LOXO-292) and pralsetinib (BLU-667) are highly potent RET-selective protein tyrosine kinase inhibitors (TKIs) for treating advanced RET-altered thyroid cancers and non-small cell lung can",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33161056",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "On May 8, 2020, the Food and Drug Administration granted accelerated approval to selpercatinib for 1) adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC), 2) adult and pediatric patients \u226512 years of age with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy, and 3) adult and pediatric patients \u226512 years of age with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33239432",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Selpercatinib, a novel, highly selective and potent, inhibitor of RET, demonstrated clinically meaningful antitumor activity with manageable toxicity in heavily pretreated and treatment-naive RET fusion-positive\u00a0non-small-cell lung cancer patients in a Phase I/II clinical trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33150799",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Selpercatinib had durable efficacy, including intracranial activity, with mainly low-grade toxic effects in patients with RET fusion-positive NSCLC who had previously received platinum-based chemotherapy and those who were previously untreated. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32846060",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "non-small-cell lung cancer, thyroid cancer, medullary thyroid cancer"
}